An Observational, Prospective Analysis of Retreatment With Bortezomib for Multiple Myeloma.

Trial Profile

An Observational, Prospective Analysis of Retreatment With Bortezomib for Multiple Myeloma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2013

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Janssen
  • Most Recent Events

    • 10 Dec 2010 Planned end date changed from 1 Nov 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top